Colorectal cancer occurs when abnormal cells develop and divide in the colon or rectum forming a mass called a tumor.
The discovery and development of a new revolutionary biomarker can provide patients and physicians with an easier method to detect colorectal cancer.
EDP Biotech has conducted clinical trials with two approved IRB's. EDP evaluated the clinical sensitivity and specificity of the ColoMarker™ ELISA immunoassay with serums from both IRB studies.
ColoMarker™ would become the first test to combine diagnostic applications with use as a patient management tool that could help physicians determine the effectiveness of colon cancer treatment in patients.